Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi 
Welcome,         Profile    Billing    Logout  
 7 Diseases   14 Trials   14 Trials   107 News 


«12
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    EVOLUTION OF MODERATE APLASTIC ANEMIA INTO SUBCLINICAL PNH/AA & SUCCESSFUL TREATMENT WITH HAPLO- BMT () -  Apr 3, 2020 - Abstract #ASPHO2020ASPHO_135;    
    Since our patient was starting college, we treated her with Immunosuppressive Therapy (IST) consisting of equine Anti-thymocyte globulin & Cyclosporine...Our patient’s LDH was normal; unlikely to respond to eculizumab... The case illustrates diagnostic challenges of patients presenting with pancytopenia; the overlap and possible evolution of disease classifications; concepts like HDA in PNH to help guide decision making; new diagnostic testing; the successful use of RIC and haplo BMT in a patient with PNH/AA and a normocellular marrow.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Trial completion:  START-DCD: A Study of Thymoglobuline (clinicaltrials.gov) -  Feb 20, 2020   
    P4,  N=115, Completed, 
    The case illustrates diagnostic challenges of patients presenting with pancytopenia; the overlap and possible evolution of disease classifications; concepts like HDA in PNH to help guide decision making; new diagnostic testing; the successful use of RIC and haplo BMT in a patient with PNH/AA and a normocellular marrow. Active, not recruiting --> Completed
  • ||||||||||  Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi, cyclosporine / Generic mfg.
    Clinical, Journal:  Aplastic anemia in children: How good is immunosuppressive therapy? (Pubmed Central) -  Dec 19, 2019   
    The available brands of ATG were similar in terms of response kinetics as well as survival. A delayed time to complete response with prolonged requirement of cyclosporine therapy was seen in the cohort.
  • ||||||||||  Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi, Promacta (eltrombopag) / Novartis
    Clinical, Journal:  The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study. (Pubmed Central) -  Jun 6, 2019   
    Twenty patients received standard IST (equine antithymocyte globulin and cyclosporine) plus eltrombopag...Although antibiotic use may have likely influenced bacterial composition and diversity, some literature suggests a decreased impact of antimicrobials on the oral microbiome as compared to their effect on the gut microbiome. Future studies with larger sample sizes that focus on the oral microbiome and the effects of antibiotics in an immunosuppressed patient population may help establish these potential associations.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Enrollment closed, Enrollment change:  START-DCD: A Study of Thymoglobuline (clinicaltrials.gov) -  Jun 6, 2019   
    P4,  N=115, Active, not recruiting, 
    Future studies with larger sample sizes that focus on the oral microbiome and the effects of antibiotics in an immunosuppressed patient population may help establish these potential associations. Recruiting --> Active, not recruiting | N=200 --> 115
  • ||||||||||  Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Journal:  Cost and Complications Are Limitations In Resource-Constrained Settings For Equine Anti-Thymocyte Globulin. (Pubmed Central) -  May 22, 2019   
    The article nicely describes the real world data of response rate of ATG-based immunosuppressive therapy in very severe aplastic anemia patients. However, we would like to add two more points, cost and complications (infectious) of ATG, to the article, which are extremely important in the resource constraints setting of developing countries.
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Trial completion date, Trial primary completion date:  START-DCD: A Study of Thymoglobuline (clinicaltrials.gov) -  Mar 19, 2019   
    P4,  N=200, Recruiting, 
    However, we would like to add two more points, cost and complications (infectious) of ATG, to the article, which are extremely important in the resource constraints setting of developing countries. Trial completion date: Jul 2020 --> Jan 2020 | Trial primary completion date: Jul 2020 --> Jan 2020
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
    Trial completion, Trial completion date, Trial primary completion date:  Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex (clinicaltrials.gov) -  Jan 24, 2019   
    P2,  N=33, Completed, 
    Trial completion date: Jul 2020 --> Jan 2020 | Trial primary completion date: Jul 2020 --> Jan 2020 Recruiting --> Completed | Trial completion date: Sep 2018 --> Mar 2020 | Trial primary completion date: Sep 2016 --> Mar 2018
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Trial completion:  Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline (clinicaltrials.gov) -  Feb 26, 2016   
    P2,  N=35, Completed, 
    Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jul 2018 --> Dec 2018 Active, not recruiting --> Completed
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi, Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
    Trial completion, Trial primary completion date:  Comparison of ATG to Thymoglobuline in Renal Transplantation (clinicaltrials.gov) -  Apr 14, 2015   
    P4,  N=40, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2011 --> Feb 2015
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Enrollment change:  GLOBAL: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (clinicaltrials.gov) -  Mar 19, 2014   
    P2/3,  N=121, Completed, 
    Trial primary completion date: Jun 2014 --> Jun 2015 N=100 --> 121
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Trial completion:  GLOBAL: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (clinicaltrials.gov) -  Mar 19, 2014   
    P2/3,  N=121, Completed, 
    N=100 --> 121 Active, not recruiting --> Completed
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Trial completion:  Thymoglobuline in Non-myeloablative Allogeneic Stem-cell Transplantation (clinicaltrials.gov) -  Feb 22, 2014   
    P3,  N=30, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    Enrollment open:  Evaluation of 3 Different Doses of IV Busulfan (clinicaltrials.gov) -  Dec 30, 2013   
    P2,  N=177, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi
    New P2 trial:  Evaluation of 3 Different Doses of IV Busulfan (clinicaltrials.gov) -  Nov 13, 2013   
    P2,  N=177, Recruiting,